Intestinal alpha-glucosidases and pancreatic alpha-amylase

Intestinal alpha-glucosidases and pancreatic alpha-amylase are key enzymes responsible for the breakdown of complex dietary carbohydrates into absorbable monosaccharides. Pancreatic alpha-amylase initiates the process by hydrolyzing starch into smaller oligosaccharides, while intestinal brush-border enzymes, such as sucrase-isomaltase and maltase-glucoamylase, complete the digestion into glucose (UniProt: P04746, O43451, P14410). In the context of metabolic disease, these enzymes are primary targets for managing postprandial hyperglycemia in patients with type 2 diabetes. By inhibiting these enzymes, drugs like acarbose and miglitol slow the rate of glucose absorption, preventing sharp spikes in blood sugar after meals (StatPearls: Alpha Glucosidase Inhibitors, 2023). This therapeutic approach focuses on the digestive tract rather than systemic insulin secretion or sensitivity. However, the presence of undigested carbohydrates in the large intestine often leads to gastrointestinal side effects due to bacterial fermentation (PubMed: PMID 22419547). These enzymes are essential for maintaining glucose homeostasis through the regulation of carbohydrate processing.

Other names

Alpha-glucosidaseAlpha-amylaseMaltase-glucoamylaseSucrase-isomaltaseMGAMSIAMY2AAMY2B1,4-alpha-D-glucan glucanohydrolaseGlucan 1,4-alpha-glucosidase

Competitive inhibition of pancreatic alpha-amylase and intestinal brush-border alpha-glucosidases (maltase, sucrase, isomaltase, and glucoamylase), which delays the hydrolysis of complex carbohydrates and disaccharides into glucose, thereby slowing glucose absorption and reducing postprandial blood glucose excursions (StatPearls: Alpha Glucosidase Inhibitors, 2023).